Degenerative eye conditions such as age-related macular degeneration (AMD), diabetic
retinopathy, and retinal vein occlusion are major contributors to significant vision loss in …

Management of vitreoretinal disorders (eg, neovascular age-related macular degeneration
[nAMD] and diabetic macular edema [DME]) have assumed the standard therapy of lifelong …

Purpose Although previous studies have demonstrated the efficacy of faricimab in treatment-
naive patients with neovascular age-related macular degeneration (nAMD), its outcomes in …

Purpose To assess the anatomic and functional outcomes in eyes with neovascular age-
related macular degeneration (nAMD) previously treated with anti-VEGF therapy in …

Background Age-related macular degeneration (AMD) remains a primary cause of
blindness, with neovascular AMD (nAMD) presenting particular treatment challenges …

Purpose A subset of patients with neovascular age-related macular degeneration (nAMD)
experience treatment burden and suboptimal response with anti-VEGF therapy. The aim of …

Background Landmark studies reported on faricimab efficacy and safety predominantly in
treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are …

Purpose To assess the 12-month outcomes of intravitreal faricimab (IVF) in treatment-
resistant neovascular age-related macular degeneration (nAMD) subjects recalcitrant to …

Purpose To report short-term outcomes of treatment switch to faricimab in real-world patients
with aflibercept-resistant neovascular age-related macular degeneration (AMD). Methods …

Purpose: To evaluate the functional and anatomic outcomes of faricimab treatment in
patients with neovascular age-related macular degeneration (nAMD) who are unresponsive …